Background: Over the last few decades, the worldwide burden of cancer has been increased. More than half of the 18.1 million people diagnosed with cancer in 2018 died. Lung cancer diagnoses and deaths are on the rise. So that it is very important to investigate the factors that influence lung cancer mortality. The aim is to assess the characteristics of lung cancer patients and the factors influencing mortality due to lung cancer. Methods: A cross-sectional observational study was performed on 58 lung cancer patients (48 with Non-Small Cell Lung cancer(NSCLC) and 10 with Small Cell Lung Cancer(SCLC) with a mean age 58.9 yrs. Fortynine of them were males, one third were current smokers and 56% of them had advanced stage of lung cancer (stage III and IV). Survival was calculated from the date of enrollment in the study to the date of the last follow-up visit (3 years) or death. Results: Seventy-five of the studied patients died with an average survival duration of 19 months for NSCLC patients in comparison to 12 months for SCLC patients. Patients > 60 yrs., those with SCLC, current smokers and those with performance status ≥ 2 had a low survival time. Univariate regression analysis identified that advanced stage of cancer had a 6-fold increase in mortality (p=0.0001). Conclusion: Age more than 60, performance status ≥ 2 and stage III and IV were found as significant independent factors linked with raised mortality rate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.